Jardiance and Bupropion Interaction: What Patients and Clinicians Need to Know

Can You Take Jardiance and Bupropion Together?

For most patients, yes, with monitoring. No dedicated pharmacokinetic interaction study of empagliflozin plus bupropion turned up in the sources reviewed for this article, and none of the primary sources checked list this pairing as requiring a dose change. That absence of a signal is meaningful but not the same as a completed safety study of the combination.

The mechanistic reason a direct interaction is unlikely is straightforward. Empagliflozin is cleared mainly by glucuronidation (UGT enzymes), while bupropion is metabolized by CYP2B6 and its active metabolite, hydroxybupropion, inhibits CYP2D6. These are separate enzyme systems, so bupropion's CYP2D6 inhibition would not be expected to change empagliflozin blood levels, per the empagliflozin clinical pharmacology review [A].

The two indirect risks worth planning around are a lower seizure threshold from bupropion, potentially compounded by empagliflozin-related volume or electrolyte shifts, and appetite suppression from bupropion adding to empagliflozin's glucose-lowering effect in patients also on insulin or a sulfonylurea.

How Each Drug Is Metabolized

Empagliflozin

Empagliflozin is glucuronidated by UGT1A3, UGT1A8, UGT1A9, and UGT2B7 into inactive metabolites, with a portion of the dose also excreted unchanged by the kidney, per prescribing information. FDA's clinical pharmacology review of the original empagliflozin application describes the in vitro and clinical drug-interaction testing that supports this metabolic profile, including the assessment of CYP- and transporter-mediated interaction potential [A]. Empagliflozin is a P-glycoprotein substrate, but bupropion is not a P-gp inhibitor, so that transport pathway is not a concern here either.

Bupropion

Bupropion is metabolized primarily by CYP2B6 to hydroxybupropion, its major active metabolite. Hydroxybupropion is a clinically significant CYP2D6 inhibitor, and the bupropion label describes meaningful increases in exposure for co-administered CYP2D6 substrates in interaction studies, per prescribing information. The exact fold-change figures reported for specific drugs (for example, older interaction data involving desipramine) should be confirmed against the current label text before being quoted to a patient or used to justify a specific dose change; we are flagging that number rather than restating it here because it could not be independently verified for this draft.

Why the Pathways Don't Collide

Empagliflozin is a UGT substrate; bupropion inhibits CYP2D6. Because empagliflozin does not depend on CYP2D6 for clearance, there is no established mechanism by which bupropion would raise or lower empagliflozin exposure [A]. There is also no known mechanism by which empagliflozin would affect bupropion or hydroxybupropion levels, since empagliflozin does not inhibit or induce CYP2B6.

The Pharmacodynamic Risks That Actually Matter

Seizure Threshold, Fluid Status, and Electrolytes

Bupropion's seizure risk rises with dose, and the drug is contraindicated in patients with a current or prior seizure disorder, per prescribing information. Separately, SGLT2 inhibitors including empagliflozin are diuretic-like in effect and can shift fluid and electrolyte status, particularly early in treatment and in patients who are older, volume-depleted, or on a diuretic, per general SGLT2 inhibitor labeling. Electrolyte disturbances, especially significant sodium or potassium shifts, are a recognized general seizure precipitant.

No study identified for this article has directly quantified how much empagliflozin-related volume or electrolyte change adds to bupropion's baseline seizure risk. The combined-risk framing here is pharmacologically plausible, not a demonstrated finding, and should be described to patients and prescribers that way. A reasonable, conservative practice is to check a basic metabolic panel at baseline and again 4 to 6 weeks after starting both drugs, and to correct any significant sodium or potassium abnormality promptly.

Euglycemic Diabetic Ketoacidosis

SGLT2 inhibitors, including empagliflozin, carry a known risk of euglycemic diabetic ketoacidosis, a state in which ketoacidosis develops without the usual marked hyperglycemia, so it can be missed by glucose monitoring alone, as flagged in past FDA safety communications. This is a real, labeled risk of empagliflozin on its own. Bupropion does not have an established mechanism for increasing ketone production, but a patient using bupropion for appetite suppression who also cuts carbohydrate intake sharply could plausibly increase ketone production through caloric restriction, independent of any drug-drug interaction. Precise incidence figures for euglycemic DKA vary across published analyses; rather than restate a single pooled rate that could not be confirmed against its cited source, the practical takeaway is that the risk is uncommon but real and should prompt ketone testing if a patient reports nausea, vomiting, or abdominal pain, even with a normal glucose reading.

Bupropion as an Appetite-Suppressing, CYP2D6-Inhibiting Comedication

Patients with type 2 diabetes are sometimes prescribed bupropion for depression or, combined with naltrexone (Contrave), as an FDA-approved weight-loss therapy. Both bupropion and naltrexone-bupropion have shown weight loss versus placebo in randomized trials [6][7], and empagliflozin itself is associated with modest weight reduction through urinary glucose loss [8]. Combining the two for weight-related goals is a plausible clinical scenario, but specific percentage weight-loss figures from these trials vary by dose, formulation, and duration across the source studies, and should be pulled directly from the trial of interest rather than treated as interchangeable.

Appetite Suppression and Hypoglycemia

Empagliflozin's glucose-lowering effect is largely glucose-dependent and carries a low hypoglycemia risk on its own, but that changes when it is combined with insulin or a sulfonylurea. Bupropion's central appetite suppression can reduce caloric intake further. In a patient already on a secretagogue or insulin, the combination of reduced intake and glucosuria is a reasonable basis for proactively reviewing (and often reducing) the insulin or sulfonylurea dose, consistent with general diabetes-care practice around adding any medication that meaningfully reduces caloric intake [10].

Cardiovascular Context

Empagliflozin reduced cardiovascular death in the EMPA-REG OUTCOME trial, one of the more robust findings in the SGLT2 inhibitor evidence base [8]. Bupropion's cardiovascular safety profile has been studied in large observational cohorts without a signal of increased serious cardiac events relative to SSRIs, though individual assessment remains appropriate in patients with established cardiovascular disease [9]. These are separate bodies of evidence about each drug individually; neither trial evaluated the two drugs together.

CYP2D6 Substrates Worth Reviewing on the Rest of the Medication List

Empagliflozin itself is not a CYP2D6 substrate, so bupropion's CYP2D6 inhibition does not affect it. But patients on empagliflozin are frequently on other drugs that are true CYP2D6 substrates, and those are the interactions that matter when bupropion is added. Commonly relevant examples include metoprolol, carvedilol, codeine, tramadol, and some tricyclic antidepressants.

For metoprolol and carvedilol, bupropion co-administration can meaningfully raise plasma levels, which is a reason to monitor heart rate and blood pressure more closely after starting bupropion in a patient on either drug. For codeine and tramadol, CYP2D6 inhibition blunts the conversion to their active analgesic metabolites while parent drug accumulates; the tramadol label separately warns that CYP2D6 inhibition can raise seizure and serotonin syndrome risk. As with the interaction magnitude noted earlier, exact fold-change numbers for any specific co-medication should be checked against the current bupropion label rather than assumed from older summaries.

Patient Populations That Warrant Extra Caution

Older adults. Volume depletion-related adverse events with empagliflozin are more commonly reported in patients 75 and older, per prescribing information. This group is also more likely to be on a CYP2D6 substrate and to have less physiologic reserve if a seizure or significant electrolyte shift occurs. A conservative approach is to avoid rapid empagliflozin up-titration and to favor bupropion doses at the lower end of the labeled range where clinically appropriate.

Patients with a seizure history. Bupropion is contraindicated in patients with a current or prior seizure disorder, per prescribing information. Empagliflozin's volume and electrolyte effects do not change that contraindication, but they are a reason to be especially cautious if bupropion is used off-label judgment in this group; specialist input is reasonable.

Patients on insulin or a sulfonylurea. Hypoglycemia risk rises when a secretagogue or insulin is combined with any agent that reduces caloric intake, including bupropion. Proactive review of the insulin or sulfonylurea dose is a reasonable default when bupropion is added [10].

Evidence-Status Map: Empagliflozin and Bupropion

A Practical Monitoring Approach

Baseline: fasting glucose or HbA1c, basic metabolic panel (sodium, potassium, creatinine, bicarbonate), blood pressure, weight, and a seizure-history check.

Weeks 2 to 6: symptom review for dizziness, dry mouth, or polyuria; repeat basic metabolic panel to catch early electrolyte drift.

3 months: repeat metabolic panel, HbA1c, weight, and a review for any new neurological symptoms.

Ongoing: reassess whether bupropion is still needed at its current dose, and recheck renal function periodically per routine diabetes care.

This cadence reflects general chronic-disease monitoring practice for patients starting a new agent with volume, electrolyte, or CNS implications rather than a specific published protocol for this drug pair.

How Interaction Databases Classify This Pair

Commercial interaction checkers vary in how they classify pharmacodynamic-only interactions like this one, and their ratings change over time as new data are reviewed. Rather than restate a specific letter grade or severity label here, which could not be verified as current for this draft, clinicians and pharmacists should check the live entry in their own reference tool (Lexicomp, Drugs.com, or an equivalent) at the time of prescribing. What the sources reviewed for this article do support is that no FDA label for either drug lists the other as requiring a specific dose adjustment, based on the labeling reviewed for each drug.

Practical Patient Counseling Points

Hydration. Empagliflozin increases urine output. Patients should maintain reasonable fluid intake and avoid prolonged fasting or heavy alcohol use, both of which compound dehydration risk.

Seizure awareness. Patients should understand that bupropion carries a dose-related seizure risk, and that dehydration or significant electrolyte loss could theoretically add to that risk. Any unusual muscle jerking, blackout, or witnessed convulsion warrants immediate medical evaluation and holding the next bupropion dose pending that evaluation.

Ketone awareness. Checking urine or blood ketones when feeling unwell, even with a normal glucose reading, is not standard advice for most people with type 2 diabetes, but it is appropriate for anyone on an SGLT2 inhibitor. Over-the-counter urine ketone strips are widely available.